Fierce Pharma
MARCH 15, 2024
Pfizer knew 2023 was going to be a challenging year of transition. But even the drugmaker was surprised by the plummeting demand for its COVID-19 products, missing badly on its 2023 guidance. | After a difficult year for Pfizer, in which its share price fell by 44%, CEO Albert Bourla’s compensation fell by 35% from $33 million in 2022 to $21.6 million in 2023.
MedCity News
MARCH 15, 2024
Tubulis’s next-generation ADC cancer drugs are designed to overcome limitations of currently available therapies in this drug class. The new financing will support clinical trial plans, but first, preclinical proof-of-concept data will be presented during the American Association for Cancer Research annual meeting.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 15, 2024
Even though the BCMA CAR-T therapy Carvykti showed a potential problem of early patient deaths in a trial, experts on the FDA’s Oncologic Drugs Advisory Committee (ODAC) still believe that the drug | Even though the BCMA CAR-T therapy Carvykti showed a potential problem of early patient deaths in a trial, experts on the FDA’s Oncologic Drugs Advisory Committee still believe that the drug’s long-term benefits outweigh its risks.
MedCity News
MARCH 15, 2024
During a keynote address at HIMSS, Hackensack Meridian Health CEO Robert Garrett outlined four priorities that should guide healthcare organizations’ AI strategies. He said that healthcare leaders need to take care to ensure their AI efforts seek to address one if not all of these.
Fierce Pharma
MARCH 15, 2024
Over the years, Singapore has attracted a suite of biopharma majors, and Novartis is no exception. | Novartis broke ground on a $256 million expansion of its biopharmaceutical production facility in Singapore. The project will introduce digitalization and automation at the site in a bid to boost manufacturing productivity and to help upskill the company’s workforce.
Pharmaceutical Commerce
MARCH 15, 2024
Reliance on foreign imports means that disruptions in the supply chain can profoundly impact the ability of individuals in the United States to get access to the medications they need.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaVoice
MARCH 15, 2024
The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.
Fierce Pharma
MARCH 15, 2024
Over the last several decades, mounting interest has positioned bioconjugate therapeutics as one of the most promising biopharmaceutical modalities. | Antibody-drug conjugates are a promising biopharma modality but specialized expertise is instrumental for successfully bringing drugs to the clinic.
MedCity News
MARCH 15, 2024
The emergence of artificial intelligence (AI) offers a glimmer of hope in the fight against STDs and has the power to revolutionize the landscape of STD detection, treatment, and prevention.
Fierce Pharma
MARCH 15, 2024
Merck's Keytruda excels in cervical cancer trial, showing an ability to extend lives. Will a broader FDA approval follow?
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
MARCH 15, 2024
The ALS Association is partnering with myTomorrows to connect patients and physicians with clinical trials using a digital platform.
Fierce Pharma
MARCH 15, 2024
Beleaguered Sanofi spinout EuroAPI can’t seem to catch a break. | Beleaguered Sanofi spinout EuroAPI can’t seem to catch a break. After reporting ballooning losses and a four-year restructuring plan last month, the company revealed Thursday that manufacturing lapses at an Italian plant have temporarily derailed its guidance for the year.
MedCity News
MARCH 15, 2024
Solera Health and Aon are collaborating to help employers manage point solution fatigue, engage members and measure ROI.
Pharmaceutical Technology
MARCH 15, 2024
Amidst the many BTK inhibitors, Breyanzi will be the first and only CAR-T cell therapy available for the treatment of CLL and SLL.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Impetus Digital
MARCH 15, 2024
This is a guest article and does not necessarily reflect the views and values of Impetus Digital. When it comes to artificial intelligence (AI), it feels like no industry has been left untouched. Even those that might not feel like a natural fit for computers are being shaped and influenced by this technology, with artists and writers utilizing it in new ways.
European Pharmaceutical Review
MARCH 15, 2024
According to research published by Coherent Market Insights, the global mycoplasma testing market is anticipated to reach $1,907.6 million by 2031. The market is set to witness a compound annual growth rate (CAGR) of 9.7 percent during the forecast period, the report predicted. What is driving and limiting growth in the market? Specifically, technology innovations such as sequencing technology, supported by “strong government funding for biomedical research” in the US has driven rapid developmen
pharmaphorum
MARCH 15, 2024
Our latest round-up of funding rounds in the digital health category features updates from Healthee, Aktiia, Moxe Health, Eleanor Health, Tava Health, BrainCheck, and Redi Health.
Pharmaceutical Technology
MARCH 15, 2024
Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
MARCH 15, 2024
Consortium led by Birmingham University unveils a centre of excellence for medicines manufacturing training using VR, to answer a UK skills shortage.
Impetus Digital
MARCH 15, 2024
A version of this article was previously published in the Journal of mHealth. The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1).
European Pharmaceutical Review
MARCH 15, 2024
Researchers have proposed an advanced analytical technology that can rapidly classify medical cannabis plants at production sites. Using the analytical technique, the plants can be classified “by chemotype using hyperspectral imaging and machine learning (ML),” Markel San Nicolas, researcher in the UPV/EHU’s IBeA group of the University of the Basque Country, and first author of the corresponding research paper explained.
Pharmaceutical Technology
MARCH 15, 2024
Madrigal’s Rezdiffra received an accelerated approval as a treatment for noncirrhotic NASH, also known as MASH.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Commerce
MARCH 15, 2024
Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.
pharmaphorum
MARCH 15, 2024
Madrigal Pharma is first pharma company to get FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH)
Eversana Intouch
MARCH 15, 2024
In a recent article published by Med Ad News and PharmaLive.com , Hattie Stearns, Senior Director of Experience DesignOps, provides five key takeaways she observed as a brand and design lead at SXSW 2024. In the article, Hattie expands on each takeaway and highlights the responsibility we have as marketers to co-create and cultivate authentically. Art meets tech for healing and community Brands getting real Designing with heart and inclusivity Learning through stories AI with a human touch “Co-c
PharmaTimes
MARCH 15, 2024
More than 3,700 cases of mpox have been identified in the UK since May 2022
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
pharmaphorum
MARCH 15, 2024
Geron rockets after FDA advisory committee backs imetelstat as a treatment for transfusion-dependent myelodysplastic syndromes
Pharmaceutical Commerce
MARCH 15, 2024
The latest news for pharma industry insiders.
PharmaTimes
MARCH 15, 2024
Every year, missed hospital appointments are estimated to cost the NHS £1.
PharmaTech
MARCH 15, 2024
Quality-by-design risk assessment workflows can be laborious and have limited capacity to connect with vast volumes of prior knowledge generated by organizations. Their digital transformation can improve efficiency, reduce human errors, and facilitate integration within a much broader digital ecosystem.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
363 
Let's personalize your content